564 related articles for article (PubMed ID: 8211211)
21. [Transfusion of platelet concentrates].
Rieux C; Lee K; Lavaud A; Bierling P
Ann Med Interne (Paris); 1999 Dec; 150(8):631-41. PubMed ID: 10686645
[TBL] [Abstract][Full Text] [Related]
22. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
[TBL] [Abstract][Full Text] [Related]
23. Acute bleeding and thrombocytopenia after bone marrow transplantation.
Nevo S; Enger C; Hartley E; Borinsky ME; Swan V; Fuller AK; Braine HG; Kickler TS; George JN; Vogelsang GB
Bone Marrow Transplant; 2001 Jan; 27(1):65-72. PubMed ID: 11244439
[TBL] [Abstract][Full Text] [Related]
24. The current status of platelet and granulocyte transfusions.
Seidl S; Kilp M
Haematologia (Budap); 1980; 13(1-4):145-54. PubMed ID: 7019021
[TBL] [Abstract][Full Text] [Related]
25. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components.
Eernisse JG; Brand A
Exp Hematol; 1981 Jan; 9(1):77-83. PubMed ID: 7238644
[TBL] [Abstract][Full Text] [Related]
26. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia.
Salama A; Kiesewetter H; Kalus U; Movassaghi K; Meyer O
Thromb Haemost; 2008 Nov; 100(5):762-5. PubMed ID: 18989518
[TBL] [Abstract][Full Text] [Related]
27. Optimizing platelet transfusion therapy.
Heal JM; Blumberg N
Blood Rev; 2004 Sep; 18(3):149-65. PubMed ID: 15183900
[TBL] [Abstract][Full Text] [Related]
28. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
Amemiya Y
Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
[TBL] [Abstract][Full Text] [Related]
29. Refractoriness to platelet transfusion following partial hepatectomy for hepatocellular carcinoma: report of two cases.
Kaibori M; Nagahama T; Yokoigawa N; Yanagida H; Nakamoto H; Kitade H; Satoi S; Onishi S; Kwon AH; Kamiyama Y
Hepatogastroenterology; 2003; 50(51):832-6. PubMed ID: 12828097
[TBL] [Abstract][Full Text] [Related]
30. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
[TBL] [Abstract][Full Text] [Related]
31. [Planning platelet support as an aid in a leukemia and bone marrow transplant unit].
Mazzara R; Puig L; Gelabert A; Ercilla G; Grañena A; Marín P; Carreras E; Rozman C; Castillo R
Sangre (Barc); 1985; 30(4-B):557-77. PubMed ID: 3909467
[No Abstract] [Full Text] [Related]
32. Guidelines for platelet transfusions. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force.
Murphy MF; Brozovic B; Murphy W; Ouwehand W; Waters AH
Transfus Med; 1992 Dec; 2(4):311-8. PubMed ID: 1339584
[TBL] [Abstract][Full Text] [Related]
33. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
Basire A; Picard C
Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
[TBL] [Abstract][Full Text] [Related]
34. Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia.
Flood VH; Johnson FL; Boshkov LK; Thomas GA; Nugent DJ; Bakke AC; Nicholson HS; Tilford D; Brown MP; Godder KT
Pediatr Blood Cancer; 2005 Dec; 45(7):971-5. PubMed ID: 15768382
[TBL] [Abstract][Full Text] [Related]
35. Refractory response to platelet transfusion therapy.
Eisenberg S
J Infus Nurs; 2010; 33(2):89-97. PubMed ID: 20228646
[TBL] [Abstract][Full Text] [Related]
36. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.
Slichter SJ; Davis K; Enright H; Braine H; Gernsheimer T; Kao KJ; Kickler T; Lee E; McFarland J; McCullough J; Rodey G; Schiffer CA; Woodson R
Blood; 2005 May; 105(10):4106-14. PubMed ID: 15692069
[TBL] [Abstract][Full Text] [Related]
37. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.
Murphy S; Snyder E; Cable R; Slichter SJ; Strauss RG; McCullough J; Lin JS; Corash L; Conlan MG;
Transfusion; 2006 Jan; 46(1):24-33. PubMed ID: 16398727
[TBL] [Abstract][Full Text] [Related]
38. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
39. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients.
Slichter SJ
J Clin Apher; 2006 Apr; 21(1):78-84. PubMed ID: 16619231
[TBL] [Abstract][Full Text] [Related]
40. Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets.
Heuer L; Blumenberg D
Blood Coagul Fibrinolysis; 2005 Jun; 16(4):287-90. PubMed ID: 15870549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
